THE ARMY, UNITED STATES DEPARTMENT OF

60 Degrees Pharmaceuticals and Tufts Medical Center signed a Patent License Agreement to advance tafenoquine for babesiosis treatment and prevention. Tafenoquine is not FDA-approved for babesiosis. The agreement includes joint patent ownership, 60 Degrees' exclusive commercialization rights, Tufts MC's research license, royalties for Tufts MC, and 60 Degrees' commitment to product development.

60 Degrees Pharmaceuticals, Inc. is conducting a double-blind, placebo-controlled trial in collaboration with Brigham and Women’s Hospital to evaluate tafenoquine combined with standard treatment for hospitalized babesiosis patients. The trial aims to assess safety and efficacy, with endpoints including time to symptom resolution and molecular cure. Recruitment of 24-33 patients is planned for summer 2025, with an interim analysis expected in early 2026.

Dr. Timothy Masterson discussed RPLND strategies for metastatic testicular seminoma at the 2024 SUO meeting, highlighting historical studies and recent trials (SEMS, PRIMETEST, COTRIMS) that support RPLND as an effective option for stage IIA/B seminoma patients, with improved survival outcomes and reduced long-term toxicities compared to radiotherapy.

60 Degrees Pharmaceuticals, Inc. launches a nine-month pilot to boost ARAKODA® (tafenoquine) awareness and usage via virtual sales and a co-pay program. ARAKODA is the only new antimalarial in over a decade, offering broad efficacy, weekly dosing, and a safe profile. The pilot aims to gather insights for a 2025 U.S. sales expansion.

Thomas A. Russo identified genetic elements transforming classical Klebsiella pneumoniae into hypervirulent strains, which can infect healthy people and become drug-resistant. Research published in eBioMedicine highlights pVir plasmid as the primary genetic determinant of hypervirulence, with potential therapeutic targets for countermeasures.